EyePoint Pharmaceuticals, Inc.

Clinical trials sponsored by EyePoint Pharmaceuticals, Inc., explained in plain language.

EyePoint Pharmaceuticals, Inc. EYPT NASDAQ

Develops ophthalmic therapies for eye diseases.

Not investment advice. Company information is shown for context only. Clinical trials frequently fail.

Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.

Upcoming readouts

Trials from this sponsor expected to report results within the next 12 months.

New eye drug could slash injection frequency for wet AMD patients Results expected Oct 2026 (estimated) May already have reported ↗ 🚀 Make-or-break

Browse trials soon ready across all sponsors →

Not yet finished but already full! 4 Completed 1

New eye injection could mean fewer doctor visits for wet AMD patients

Disease control Completed

This phase 2 trial tested a new drug called EYP-1901, given as an eye injection, for people with wet age-related macular degeneration (AMD). The goal was to see if it works as well as the standard treatment, aflibercept (Eylea), but with fewer injections. 161 participants receive…

Phase 2 • Sponsor: EyePoint Pharmaceuticals, Inc. • Aim: Disease control

Last updated Jun 27, 2026 07:54 UTC

EyePoint Pharmaceuticals, Inc.

Upcoming readouts

New eye injection could mean fewer doctor visits for wet AMD patients